"Vasodilator Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs used to cause dilation of the blood vessels.
| Descriptor ID |
D014665
|
| MeSH Number(s) |
D27.505.954.411.918
|
| Concept/Terms |
Vasodilator Agents- Vasodilator Agents
- Agents, Vasodilator
- Vasodilators
- Vasorelaxants
- Vasodilator Drugs
- Drugs, Vasodilator
|
Below are MeSH descriptors whose meaning is more general than "Vasodilator Agents".
Below are MeSH descriptors whose meaning is more specific than "Vasodilator Agents".
This graph shows the total number of publications written about "Vasodilator Agents" by people in this website by year, and whether "Vasodilator Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 1995 | 2 | 0 | 2 |
| 1996 | 2 | 4 | 6 |
| 1997 | 2 | 3 | 5 |
| 1998 | 1 | 1 | 2 |
| 1999 | 2 | 0 | 2 |
| 2000 | 1 | 0 | 1 |
| 2001 | 1 | 1 | 2 |
| 2002 | 2 | 1 | 3 |
| 2003 | 4 | 1 | 5 |
| 2004 | 2 | 1 | 3 |
| 2005 | 3 | 1 | 4 |
| 2006 | 5 | 2 | 7 |
| 2007 | 1 | 3 | 4 |
| 2008 | 2 | 1 | 3 |
| 2009 | 1 | 1 | 2 |
| 2010 | 5 | 4 | 9 |
| 2011 | 2 | 1 | 3 |
| 2012 | 1 | 0 | 1 |
| 2013 | 0 | 2 | 2 |
| 2014 | 1 | 1 | 2 |
| 2015 | 3 | 0 | 3 |
| 2016 | 5 | 4 | 9 |
| 2017 | 3 | 4 | 7 |
| 2018 | 0 | 1 | 1 |
| 2019 | 3 | 1 | 4 |
| 2020 | 2 | 1 | 3 |
| 2021 | 1 | 1 | 2 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Vasodilator Agents" by people in Profiles.
-
Use of Levosimendan in Patients with Pulmonary Hypertension: What is the Current Evidence? Drugs. 2023 Feb; 83(3):195-201.
-
Hemodynamic reserve predicts early right heart failure after LVAD implantation. J Heart Lung Transplant. 2022 Dec; 41(12):1716-1726.
-
Natriuretic peptide-based inclusion criteria in heart failure with preserved ejection fraction clinical trials: insights from PARAGON-HF. Eur J Heart Fail. 2022 04; 24(4):672-677.
-
Effect of Poloxamer 188 vs Placebo on Painful Vaso-Occlusive Episodes in Children and Adults With Sickle Cell Disease: A Randomized Clinical Trial. JAMA. 2021 04 20; 325(15):1513-1523.
-
Nonresponse to Acute Vasodilator Challenge and Prognosis in Heart Failure With Pulmonary Hypertension. J Card Fail. 2021 08; 27(8):869-876.
-
Pulmonary Artery Wedge Pressure Respiratory Variation Increases With Sodium Nitroprusside Vasodilator Challenge. J Card Fail. 2020 Dec; 26(12):1096-1099.
-
Recurrent but Preventable Pulseless Electrical Activity Arrest: Follow the Guidelines! Circ Heart Fail. 2020 03; 13(3):e006781.
-
Comprehensive Diagnostic Evaluation of Cardiovascular Physiology in Patients With Pulmonary Vascular Disease: Insights From the PVDOMICS Program. Circ Heart Fail. 2020 03; 13(3):e006363.
-
Effectiveness, Safety, and Economic Comparison of Inhaled Epoprostenol Brands, Flolan and Veletri, in Acute Respiratory Distress Syndrome. Ann Pharmacother. 2020 05; 54(5):434-441.
-
Utilization of inhaled nitric oxide after surgical repair of truncus arteriosus: A multicenter analysis. Congenit Heart Dis. 2019 Nov; 14(6):1078-1086.